Drug intelligence / Profile preview

measles, mumps, rubella and varicella vaccine (live)

Development stage
Approved
Lead developer
Merck
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

The measles-mumps-rubella-varicella (MMRV) vaccine is a live attenuated combination biologic used for the active immunization of children against four viral diseases: measles, mumps, rubella, and varicella (chickenpox). By combining these antigens into a single injection, the vaccine simplifies pediatric immunization schedules and improves compliance. Commercially available versions include Merck's ProQuad and GSK's Priorix-Tetra. The vaccine works by inducing a humoral and cellular immune response against the respective viruses, providing long-term protection. In clinical studies, it is often evaluated for safety and immunogenicity when co-administered with other routine pediatric vaccines like meningococcal conjugate vaccines (e.g., Menactra).

Brand names
ProQuadPriorix-Tetra
Other names
MMRVMMRV vaccinemeasles-mumps-rubella-varicella vaccine
02

Targets

Measles virus entry receptorsSia (Alpha-2,3-linked sialic acid receptor)CADM1 (Cell adhesion molecule 1)

Beyond the preview

Go deeper on measles, mumps, rubella and varicella vaccine (live).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on measles, mumps, rubella and varicella vaccine (live).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call